Literature DB >> 8080994

Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation.

S Fournier1, M Rubio, G Delespesse, M Sarfati.   

Abstract

CD23 gene is overexpressed and abnormally regulated in the most frequent adult leukemic disorder, B chronic lymphocytic leukemia (B-CLL). Switch on and off in the upregulation of surface CD23 expression consistently occurs in the early stage of normal B-cell activation, suggesting a key role for CD23 in this process. We show here that, after ligation of mlg in the presence of interleukin-4, the increase of CD23 protein precedes B-cell DNA synthesis and mainly results from the strong induction of CD23 type-B isoform. Exposure of normal B cells to conventional or phosphorothioate-derivatized CD23 antisense oligonucleotides (predominantly type B) significantly augments B-cell proliferation induced by antigen receptor stimulation or direct contact with activated T cells. Unexpectedly, CD23 antisense, but not sense, oligonucleotides specifically enhance rather than suppress CD23 expression on B cells. Finally, a selective increase in CD23 type-B expression provokes the entry of resting (Go) CLL B cells into G1 and S phase of the cell cycle in the absence of any other stimulus, whereas it synergizes with tumor necrosis factor-alpha to increase the number of activated B cells. These results provide compelling evidence that CD23 represents an important molecule directly involved in the process of normal or leukemic B-cell activation and growth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080994

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  CD23/FcεRII: molecular multi-tasking.

Authors:  M Acharya; G Borland; A L Edkins; L M Maclellan; J Matheson; B W Ozanne; W Cushley
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

2.  Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters.

Authors:  Vladimir Jurisic; Natasa Colovic; Nada Kraguljac; Henry Dushan Atkinson; Milica Colovic
Journal:  Med Oncol       Date:  2008-01-09       Impact factor: 3.064

3.  A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis.

Authors:  Sarah Bradshaw; W Jim Zheng; Lam C Tsoi; Gary Gilkeson; Xian K Zhang
Journal:  Clin Immunol       Date:  2008-08-09       Impact factor: 3.969

Review 4.  Making (anti)sense of non-coding sequence conservation.

Authors:  D J Lipman
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

5.  Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.

Authors:  M P Purdue; Q Lan; T J Kemp; A Hildesheim; S J Weinstein; J N Hofmann; J Virtamo; D Albanes; L A Pinto; N Rothman
Journal:  Leukemia       Date:  2014-01-08       Impact factor: 11.528

Review 6.  Anti-CD23.

Authors:  Lanny J Rosenwasser; Jianfeng Meng
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

Review 7.  New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia.

Authors:  C M Wendtner; B Schmitt; M Bergmann; T Röhnisch; R Buhmann; M Hallek
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319

8.  Soluble CD23 levels are inversely associated with atopy and parasite-specific IgE levels but not with polyclonal IgE levels in people exposed to helminth infection.

Authors:  Nadine Rujeni; Norman Nausch; Nicholas Midzi; Reginald Gwisai; Takafira Mduluza; David W Taylor; Francisca Mutapi
Journal:  Int Arch Allergy Immunol       Date:  2013-05-14       Impact factor: 2.749

Review 9.  The role of CD23 in the regulation of allergic responses.

Authors:  Paul Engeroff; Monique Vogel
Journal:  Allergy       Date:  2021-01-16       Impact factor: 13.146

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.